Arthrex Biotech

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

Total raised

€1.5M

€1,500,000

Funding rounds

Investors

distinct backers

Active since

2020-08

latest 2020-08

Funding by year

EUR raised per year

High confidence

Raise-next likelihood11

base rate 30% for Other

Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.

1 rounds

Date	Stage	Amount	Investors
2020-09-01	Other	€1.5M	Invivo Capital Partners	View deal →

same sector or country